GSK Cancer Vaccine Fails to Meet Phase III Primary Endpoints Again

Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population March 20, 2014 GlaxoSmithKline plc (GSK) today announced that analysis of the MAGRIT trial, a phase …

Lung Cancer vaccine CimaVax-EGF – CIM Cuba

At the recent World Vaccine Congress Washington in April 2012 we had the pleasure of welcoming Dr Diego Venegas Ojeda, as one of our speakers. Dr Venegas is an Oncologist and Assistant Professor of Faculty of Medicine “Alberto Hurtado” at the Universidad Peruana Cayetano Heredia, Committee Immunology Cancer of Latin American Immunology Association. Dr Venegas worked very closely with the …